The clinical trial application for the replication deficient monkeypox vaccine developed by Chinese biotechnology has been accepted

Tech 2023-07-15 02:47:36 Source: Network

On July 13, the application for clinical trial of replication defective monkeypox vaccine independently developed by Sinopharm China Biotech Beijing Institute of Biological Products was officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration.Monkeypox is a kind of zoonotic viral disease caused by Monkeypox virus (MPXV), which is characterized by fever, rash and Lymphadenopathy

On July 13, the application for clinical trial of replication defective monkeypox vaccine independently developed by Sinopharm China Biotech Beijing Institute of Biological Products was officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration.

Monkeypox is a kind of zoonotic viral disease caused by Monkeypox virus (MPXV), which is characterized by fever, rash and Lymphadenopathy.

The main source of infection is rodents infected with Monkeypox virus. Primates (including monkeys, chimpanzees, humans, etc.) can also become sources of infection after infection.

According to the Guidelines for Diagnosis and Treatment of Monkeypox (2022 Edition) issued by the National Health Commission, Monkeypox virus is classified as Orthopoxvirus of Poxviridae, one of the four Orthopoxvirus genera that cause disease to humans (the other three are smallpox virus, vaccinia virus and vaccinia virus), and its Pathogen transmission is:

The virus invades the human body through mucous membranes and damaged skin.

Human beings are mainly infected by contacting Exudate, blood and other body fluids of infected animals, or by being bitten or scratched by infected animals.

Transmission between individuals is mainly through close contact, and can also be transmitted through droplets. Contact with items contaminated with the virus can also lead to infection, and it can also be transmitted vertically through the placenta. Sexual transmission cannot be ruled out yet.

Previously, confirmed cases of monkeypox have been reported in multiple regions of China, and there have been cases of local transmission. For Monkeypox virus, there is no specific anti Monkeypox virus drug or specific vaccine developed specifically for Monkeypox virus in China.

China Biological Beijing Institute of Biological Products quickly launched the vaccine R&D response mechanism and developed the monkeypox vaccine, which played a positive role in the prevention and control of Monkeypox virus in China.

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])

Mobile advertising space rental

Tag: The clinical trial application for the replication deficient monkeypox